OxySure and Medizon B.V. Sign Distribution Agreement for Netherlands, Belgium and Luxembourg
Frisco, Texas, USA and Fulda, Germany, May 14, 2013 – OxySure Systems, Inc. (OXYS: OTCQB) (“OxySure,” or the “Company”), a medical device innovator of life-saving, easy-to-use emergency oxygen solutions with its “oxygen from powder” technology, today announced that Medizon B.V. (“Medizon”) has signed an agreement to be the Company’s exclusive distributor for OxySure’s products in the “Benelux” countries – the Netherlands, Belgium and Luxembourg. This agreement expands OxySure’s distribution to nine countries outside the U.S.
Speaking from RETTMobil, the leading annual European Exhibition for Rescue and Mobility in Fulda, Germany Mr. Marcus Flipsen, General Manager of Medizon stated: “Medizon is absolutely delighted to partner with OxySure and to be launching OxySure here at RETTMobil. As the market leader in the sale, marketing and management of AEDs in the Netherlands, we believe the OxySure Model 615 is another “first” for us and for Benelux and is an excellent companion product to our AEDs, both our sizable installed base as well to be bundled with new AEDs being shipped going forward. We look forward to working with Julian Ross and his team to rapidly develop our markets for OxySure.”
The agreements also provide that Medizon purchase a minimum combined quantity of 2,250 units of OxySure Model 615 during the first two years subsequent to CE Marking approval. Of the Benelux countries the Netherlands is the largest market with approximately 80,000 AEDs installed.
A video animation showing the use of OxySure in English, German and Dutch can be viewed here:
http://www.youtube.com/watch?v=X96bc-Vx3aM
The website for OxySure Benelux can be viewed here:
About OxySure Systems, Inc.
OxySure Systems, Inc. (OTCQB : OXYS) is a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions. The company pioneered a safe and easy to use solution to produce medically pure (USP) oxygen from inert powders. The company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems. OxySure’s products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other “Immediately Dangerous to Life or Health” (IDLH) environments. www.OxySure.com
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts, including, without limitation, statements that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development, may be deemed to be forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import also identify forward-looking statements. These statements are subject to risks and uncertainties. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Except as may be required under applicable law, we assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of OxySure Systems, Inc. can be found in the filings of OxySure Systems, Inc. with the U.S. Securities and Exchange Commission.
Contacts:
Investor Relations, US West:
MZ North America
Ted Haberfield, President
Tel: +1-760-755-2716
Email: thaberfield@mzgroup.us
Web: www.mzgroup.us
Investor Relations, US East:
Barwicki Investor Relations
Andrew Barwicki, President
Tel: +1-516-662-9461
Email: andrew@barwicki.com
Media Relations:
Chris Castaldo
Tel: +1-516-656-0217
Email: chriscastaldo@aol.com
Netherlands/Belgium/Luxembourg:
Marcus Flipsen
Tel: +31 (0) 50 3133096
Email: m.flipsen@medizon.nl
Tags: